Lv6
1690 积分 2024-04-03 加入
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
7天前
已完结
Emerging importance of HER3 in tumorigenesis and cancer therapy
8天前
已完结
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial
8天前
已完结
Gastric Cancer: A Review
9天前
已完结
Top companies and drugs by sales in 2025
11天前
已关闭
Top companies and drugs by sales in 2025
11天前
已关闭
Claudin proteins as emerging therapeutic targets for solid tumours
15天前
已完结
Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey
1个月前
已完结
Paraffin section storage and immunohistochemistry. Effects of time, temperature, fixation, and retrieval protocol with emphasis on p53 protein and MIB1 antigen
2个月前
已关闭
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
2个月前
已完结
皖公网安备34019202002308
